Christopher Cannon/LinkedIn
Oct 3, 2025, 11:50
Christopher Cannon on Evolocumab – Landmark Phase 3 Trial Shows Benefit in Those at High Risk of CV Events
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared on LinkedIn:
”Late-breaking news!!!
PCSK9 inhibition with evolocumab shows benefit in those at high risk of CV events, (in addition to secondary prevention as shown in FOURIER)”
Read the full article here.
Article: Landmark Phase 3 Trial (Vesalius-CV) Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients
Stay updated on the latest scientific breakthroughs with Hemostasis Today.
-
May 23, 2026, 08:15Alexander Krupp: Asundexian Receives Priority Review Designation from China‘s NMPA
-
May 23, 2026, 07:59Toward a Dedicated Framework for MIg-Driven Hemostatic Disorders – JTH
-
May 23, 2026, 07:53Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
-
May 23, 2026, 07:43Ted Roh: Indonesia’s Plasma Fractionation Plant Wins Social Infrastructure Deal of the Year at the IJGlobal Awards 2025
-
May 23, 2026, 07:36Angie Read: Stories of Strength and Resilience on The Latest Episode of Stroke Sisters
-
May 23, 2026, 07:30Ozlem Fidanci: Reflections From WHA79 on the Future of Stroke Care
-
May 23, 2026, 07:21Ney Carter Borges: Where the Benefit Appears in Dual Antiplatelet Therapy
-
May 23, 2026, 05:38SIUH Advances Precision Stroke Care with Vena MicroAngioscope – Northwell Health
-
May 23, 2026, 05:31Kalyan Roy: Precision Blood Matching in Transfusion-Dependent Thalassaemia